Myositis induced by durvalumab in a patient with non‐small cell lung cancer: A case report

Immune checkpoint inhibition is associated with a broad spectrum of immune toxicities referred to as immune‐related adverse events (irAEs). Myositis is known to be a potentially fatal irAE. Here, we report a case of immune‐related myositis after the administration of durvalumab. A 60‐year‐old man wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Miyuki, Saiki, Masafumi, Omori, Chisa, Ide, Shuichiro, Masuda, Kazuki, Sogami, Yusuke, Hata, Takanori, Ishihara, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705624/
https://www.ncbi.nlm.nih.gov/pubmed/33103845
http://dx.doi.org/10.1111/1759-7714.13709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705624/
https://www.ncbi.nlm.nih.gov/pubmed/33103845
http://dx.doi.org/10.1111/1759-7714.13709

Ejemplares similares